Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

26.23 +0.44 (+1.69%)
Streaming Delayed Price Updated: 9:56 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 212,418
Open 25.47
Bid (Size) 26.16 (1)
Ask (Size) 26.29 (2)
Prev. Close 25.79
Today's Range 25.42 - 26.38
52wk Range 13.53 - 35.25
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts
New York, NY – October 9, 2025 – In a significant move set to ripple through the biotech sector, Jefferies has initiated coverage of Beam Therapeutics (NASDAQ: BEAM) with a coveted "Buy" rating. This... 
Via MarketMinute
Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves
Jim Cramer recommends buying Affirm Holdings (AFRM) on CNBC's Mad Money Lightning Round. Analysts also support Beam Therapeutics (BEAM) and Shopify (SHOP). 
Via Benzinga
Topics Artificial Intelligence

Performance

YTD
+6.2%
+6.2%
1 Month
+14.5%
+14.5%
3 Month
+28.2%
+28.2%
6 Month
+54.3%
+54.3%
1 Year
-1.7%
-1.7%

More News

Read More
Is Beam Therapeutics Gaining or Losing Market Support?
Via Benzinga
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
Via Benzinga
What Does the Market Think About Beam Therapeutics?
Via Benzinga
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
Via Benzinga
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
Via The Motley Fool
Topics Artificial Intelligence
Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies
Via Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Via Investor's Business Daily
Topics Government
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Via Benzinga
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
Via Investor's Business Daily
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab
Via Benzinga
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
BioMedNewsBreaks — Beam Therapeutics Inc. (NASDAQ: BEAM) to Present New Sickle Cell Data from BEACON Trial at EHA2025
Via Investor Brand Network
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
10 Analysts Assess Beam Therapeutics: What You Need To Know
Via Benzinga

Frequently Asked Questions

Is Beam Therapeutics Inc. - Common Stock publicly traded?
Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Beam Therapeutics Inc. - Common Stock trade on?
Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?
The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market
What is the current price of Beam Therapeutics Inc. - Common Stock?
The current price of Beam Therapeutics Inc. - Common Stock is 26.23
When was Beam Therapeutics Inc. - Common Stock last traded?
The last trade of Beam Therapeutics Inc. - Common Stock was at 10/17/25 09:56 AM ET
What is the market capitalization of Beam Therapeutics Inc. - Common Stock?
The market capitalization of Beam Therapeutics Inc. - Common Stock is 2.08B
How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?
Beam Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.